Suitability of long-acting metoclopramide for prophylaxis of chemotherapy-induced delayed nausea and vomiting.

Arzneimittelforschung

Haematology/Oncology Unit, Department of Medicine C, Kantonsspital, Nuremberg, Fed. Rep. of Germany.

Published: November 1989

Delayed nausea and emesis are common after cancer chemotherapy, especially cisplatin-containing regimens. Often no, or inadequate, prophylactic antiemetic cover is prescribed in these usually ambulant patients. Metoclopramide is a very effective drug in preventing the acute emetic and nauseating effects of cisplatin. The long-acting metoclopramide formulations (in the present study: Gastrosil retard) may be effective in preventing the delayed toxicity. 12-hourly dosing of 60 mg long-acting metoclopramide in a typical oncology ward situation led to stable metoclopramide levels of approximately 100ng/ml in the observed 74 h in 18 patients, with the well-known wide plasma concentration variability. The clinical efficacy of long-acting metoclopramide in this indication remains to be evaluated.

Download full-text PDF

Source

Publication Analysis

Top Keywords

long-acting metoclopramide
16
delayed nausea
8
metoclopramide
6
suitability long-acting
4
metoclopramide prophylaxis
4
prophylaxis chemotherapy-induced
4
chemotherapy-induced delayed
4
nausea vomiting
4
vomiting delayed
4
nausea emesis
4

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!